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Abstract
Background: Picornaviruses comprise a family of small, non-
enveloped RNA viruses. A common feature amongst many
picornaviruses is a hydrophobic pocket in the core of VP1, one
of the viral capsid proteins. The pocket is normally occupied by a
mixture of unidentified, fatty acid-like moieties, which can be
competed out by a family of capsid-binding, antiviral compounds.
Many members of the Picornaviridae family are pathogenic to
both humans and livestock, yet no adequate therapeutics exist
despite over a decade’s worth of research in the field. To address
this challenge, we developed a strategy for rapid identification of
capsid-binding anti-picornaviral ligands. The approach we took
involved synthesizing structurally biased combinatorial libraries
that had been targeted to the VP1 pocket of poliovirus and
rhinovirus. The libraries are screened for candidate ligands with a
high throughput mass spectrometry assay.
Results : Using the mass spectrometry assay, we were able
to identify eight compounds from a targeted library of 75
compounds. The antiviral activity of these candidates was assessed
by (i) measuring the effect on the kinetics of viral uncoating and
(ii) the protective effect of each drug in traditional cell-based
assays. All eight of the candidates exhibited antiviral activity, but
three of them were particularly effective against poliovirus and
rhinovirus.
Conclusions: The results illustrate the utility of combining
structure-based design with combinatorial chemistry. The success
of our approach suggests that assessment of small, targeted
libraries, which query specific chemical properties, may be the best
strategy for surveying all of chemical space for ideal anti-
picornaviral compounds. ß 2001 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
Picornaviruses comprise a family of small, non-enve-
loped viruses containing a positive-sense RNA genome
encased in a protein capsid (for a review, see [1]). The
picornavirus family is subdivided into ¢ve genera: the
apthoviruses, the cardioviruses, the hepatoviruses, the rhi-
noviruses and the enteroviruses. The hepatoviruses, rhino-
viruses and enteroviruses are responsible for a wide array
of human illnesses. The enteroviruses, which include the
polioviruses, echoviruses and coxsackieviruses, are associ-
ated with poliomyelitis, myocarditis, aseptic meningitis
and encephalitis. The rhinoviruses encompass over 100
di¡erent serotypes and are responsible for roughly 40%
of all common colds. Currently, there are no commercially
available drug therapies for any of the diseases caused by
picornaviruses.
These viruses share a common icosahedral capsid archi-
tecture constructed from 60 copies of four proteins (VP1,
VP2, VP3 and VP4) as revealed by crystallographic studies
of human coxsackievirus type B3 [2], echovirus 1 [3], po-
liovirus type 1 [4], 2 [5] and 3 [6], and rhinovirus types 1A
[7], 3 [8], 14 [9] and 16 [10]. In all of these structures the
virus surface is punctuated by broad depressions, or can-
yons, that separate prominent star-shaped mesas at the
¢ve-fold axes and propeller-like features surrounding the
three-fold axes of the particle. The canyon has been shown
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to be the site of receptor attachment for major group
rhinoviruses and for poliovirus (reviewed in [11]). At the
base of the canyon there is an opening into the hydro-
phobic core of VP1. In most of the entero- and rhinovirus
structures solved to date the core of VP1 is ¢lled with a
long, thin, worm-like density feature. This ambiguous fea-
ture has been dubbed the ‘pocket factor’ and is generally
modeled as sphingosine [6], palmitate [3], or myristate [2],
though its true chemical identity remains unknown.
In 1979, investigators at Sterling-Winthrop identi¢ed a
new antiviral compound, arildone, that bound to the vi-
rion of polio and closely related viruses [12]. Since then, a
number of antivirals, primarily targeting rhinoviruses,
have been developed (for a review, see [13]). Structural
studies of virus^drug complexes have shown that these
compounds displace the pocket factor and bind in the
hydrophobic core of VP1 [5,14^17]. Drug binding has
been shown to inhibit infectivity by two di¡erent mecha-
nisms, which are not mutually exclusive. The transition to
the A particle, which mediates cell entry, requires large-
scale changes in the capsid structure, including the loss of
VP4 and the exposure of residues 1^80 of VP1, which are
internal to the N particle. The stabilization of the virus
that occurs upon drug binding has been recently shown to
be due to a novel entropic e¡ect imparted by ligand bind-
ing [18], and not through rigidi¢cation of the capsid as has
been previously suggested [13,14]. Secondly, for some rhi-
noviruses, drug binding induces small local conformation-
al changes in loops at the base of the canyon that prevent
receptor attachment [19,20,34]. Dove and Racaniello re-
cently have shown that drug binding (which does not af-
fect receptor binding at physiological temperatures) inter-
feres with poliovirus receptor attachment at 4‡C [21]. Since
drug binding by poliovirus does not result in signi¢cant
local structural changes at the base of the canyon [17],
these results may suggest that inhibition of receptor at-
tachment also may be attributed to the ability of drugs
to inhibit small energy-dependent conformational altera-
tions required for tight receptor binding.
The predominantly hydrophobic nature of the binding
site and the unusual mechanism of action of the capsid-
binding drugs present a number of challenges to tradition-
al structure-based and other so-called rational drug dis-
covery approaches. However, the wealth of structural
data on complexes of these drugs with representative rhi-
no-, polio- and coxsackieviruses [2,4^10] makes this an
excellent test system for developing tools to aid in the
development of drugs directed at non-enzyme targets. In-
vestigators at Sterling-Winthrop and, more recently, Viro-
pharma have collaborated with Michael Rossmann’s lab-
oratory at Purdue to use structures of virus^drug
complexes in the late stages drug development. One of
the products of this e¡ort, pleconaril, is undergoing clin-
ical trials for the treatment of enterovirus induced ence-
phalitis and for rhinovirus induced colds. We have under-
taken an alternative approach, which employs a hybrid of
structure-based design into the VP1 binding sites and com-
binatorial chemistry to develop potential new leads for this
family of capsid-binding drugs.
In work that has been published previously, the design
was initiated by characterizing the ligand binding site in
the hydrophobic core of VP1 using the program MCSS
[22]. MCSS produces maps of the preferred binding sites
of small molecular fragments by simultaneously subjecting
thousands of randomly placed copies of fragments to en-
ergy minimization within the force ¢eld of a macromolec-
ular target [23]. Fragment maps centered on the VP1 core
of the poliovirus and the rhinovirus capsid were calculated
for a number of functional groups. These maps immedi-
ately suggested a template for a class of ligands which
di¡ered signi¢cantly from any of the capsid-binding drugs
that were published at that time [22]. Limited combinato-
rial libraries of ligands resembling this template were syn-
thesized and screened using a high-throughput assay [24]
in which virus is incubated with crude libraries and the
components that bind are identi¢ed by mass spectrometry.
An initial screen of a prototype library containing 75 com-
pounds identi¢ed eight possible candidates. Because the
initial screen with the full library was very noisy, potential
binders were re-synthesized as members of smaller six
compound sub-libraries. These sub-libraries were re-
screened with the mass spectrometry assay to con¢rm
the previous results and tested for reduction of the rate
constant for uncoating with an immunoprecipitation as-
say. Promising leads were individually synthesized and
also tested for their e¡ect on the rate constant of uncoat-
ing and inhibition of in vitro cell lysis. These secondary
screens yielded three compounds that inhibit uncoating
and infectivity of the Mahoney strain of type 1 (P1/Ma-
honey) poliovirus with MICs in the 0.1^10 WM range
(where the MIC is the minimum concentration required
to inhibit viral replication in a tissue culture-based assay).
The compound with the highest activity against type 1
poliovirus also had an IC50 in the 0.1 WM range when
assayed with two di¡erent serotypes of rhinoviruses (where
the IC50 is the concentration required to reduce infectivity
by 50%).
2. Results
2.1. Assay development using a radiolabeled
anti-picornaviral compound
A diagram of the mass spectrometric screening assay is
shown in Fig. 1. The ability of the assay to isolate and
detect complexes with ligands whose a⁄nities are at the
lower limit of the range for acceptable leads (V1^10 WM)
was determined by using 3H-R77975 (Fig. 2A; Janssen
Pharmaceutica), which has a MIC of 3.061 WM for
P1/Mahoney [17]. P1/Mahoney was incubated overnight at
4‡C in a 8U1036 M 3H-R77975 solution (4U1039 mol)
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with a VP1 pocket:compound ratio of 1:1. Virus^drug
complexes were isolated by low pressure size exclusion
chromatography on a Sephacryl S-300 column
(8.5 cm length, 1.3 cm diameter). The void volume, con-
taining virus and presumably drug, was collected in frac-
tions 8^10. The passage of 3H-R77975 through the column
was monitored by scintillation counting of aliquots from
each fraction. The amount of 3H-R77975 that eluted with
the virus amounted to roughly 33% of the counts incu-
bated with the virus (Table 1, column A). The remainder
of the counts eluted as a broad peak, suggesting that a
Fig. 1. Schematic of high-throughput mass spectrometry screen. (#1) Vi-
rus is incubated with a compound or mixture of compounds. (#2) Since
the virus molecular mass (8.5U1036 Da) is much greater than that of
the compounds tested, compounds unbound to the virus are easily sepa-
rated from virus^compound complexes by size exclusion chromatogra-
phy. (#3) The complexes are then denatured with an organic solvent,
which separates the hydrophobic compounds from the virus into an or-
ganic phase. (#4) The organic phase is dried down and the residue ana-
lyzed by mass spectrometry.
Fig. 2. Schematic of compounds. (A) Janssen Pharmaceutica com-
pounds. (B) Structurally related analogs of Janssen compounds thought
to have no a⁄nity for P1/Mahoney by prior crystallographic analysis.
Molecular masses are given in Da in parentheses.
Table 1
Assessing assay yield and selectivity with a radiolabeled ligand
A B C
3H-R77975+PV (%) 3H-R77975 only (%) 3H-R77975+R78206+PV (%)
Incubation cpm 100 100 100
Void volume cpm 33 0 0
Extracted cpm 28 0 0
CPM after drying and re-suspending in AcN 24 0 0
For all columns, 100% represents the total number of counts used in the incubation and each value given below is a percentage of the initial cpm.
A: P1/Mahoney incubated with 3H-R77975. B: No 3H-R77975 is recovered in the void volume if there is no virus in the incubation. C: In the presence
of R78206, a more potent inhibitor than R77975, no counts are recovered in the void volume.
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signi¢cant fraction of the bound drug dissociated during
the course of separation (data not shown). This is consis-
tent with the expectation that the o¡-rate of this poorly
binding ligand is high. The peak fractions from the void
volume peak were pooled. Two volumes of ethyl acetate
were added and the mixture vortexed in order to denature
the virus and partition 3H-R77975 into an organic phase
for an easy one-step puri¢cation. After the ethyl acetate
Fig. 3. Schematic of libraries. (A) Schematic of library A. (B) Sub-library 6.1. (C) Sub-library 6.2. Each compound in (B) and (C) is identi¢ed by its
corresponding mass. Compounds denoted 2 were initially identi¢ed in our library A screens. When each sub-library was tested with the mass spectrome-
try assay, all compounds marked with an asterisk (*) were found to be associated with virus.
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layer was removed and transferred to a fresh Eppendorf
tube, 10% of this material was removed and the cpm de-
termined. The extraction step recovered an estimated 85%
of the material present in the original peak. After vacuum
drying the ethyl acetate away and re-suspending the resi-
due in acetonitrile (AcN), roughly 80% of the extracted
material was recovered. When no virus was used in the
incubation, the amount of counts in the void volume cor-
responded to the background (Table 1, column B).
Selectivity of the assay was shown by a competition
experiment (Table 1, column C) using R78206 (Fig. 2A),
which has a MIC of 8 nM [17], nearly a 1000-fold greater
a⁄nity for P1/Mahoney than R77975. In this control ex-
periment, equal concentrations of 3H-R77975 and R78206
(8 WM, corresponding to 2U10310 mol of each drug in the
assay) were incubated with virus (2U10311 mol binding
sites). As expected the presence of the higher a⁄nity li-
gand (R78206) at a 10-fold excess over available sites re-
sulted in the exclusion of the labeled low a⁄nity ligand
(R77975).
In order to avoid the dissociation of weakly binding
ligands during the development of the low pressure size
exclusion separation of virus^drug complexes, all subse-
quent experiments were performed using a spin column
(BioRad), which allows recovery of the void volume with-
in 4 min.
2.2. Mass spectrometry screenings of R78206, R77975 and
R80633 incubated with virus
Before using the assay to identify ligands in experimen-
tal combinatorial libraries (Fig. 3) several control experi-
ments were performed using mixtures of Janssen com-
pounds. To show that the assay was capable of isolating
multiple compounds, three Janssen compounds, R77975,
R80633 and R78206 (Fig. 2A), were incubated with virus
to allow binding. The results of this assay are shown in
Fig. 4A. All three compounds are present in equimolar
amounts (concentration 4 WM which corresponds to
C
Fig. 4. Validation of mass spectrometry assay. (A) Mass spectrum illus-
trating that R77975, R78206 and R80633 are recovered from our polio-
virus binding assay. (B) Mass spectrum showing that the binding assay
is selective. In this experiment, the virus had been incubated with
R78206, R80633 and ¢ve other compounds with no known ability to
bind poliovirus as judged from previous crystallographic assays (Fig.
2B). IQ may be a weak binder as suggested by our assay. (C) R77975,
R78206 and R80633 incubated without virus. The absence of virus in
the incubation prevents the low molecular mass compounds from ap-
pearing in the void volume. (D) An incubation with virus only. No
mass peaks for any of the tested compounds are visible. M corresponds
to one of the K-cyano-4-hydrocinnamic acid matrix peaks used in these
assays. Its [M+H] peak is 379.4. The molecular masses of the tested
compounds are: R77975 = 369, R78206 = 383, R80633 = 397, IQ = 360,
IR 310, CA = 370, CB = 304 and OA = 354.
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2U1039 mol of each compound), and the virus concentra-
tion was set such that there were exactly enough sites to
bind the total number of compounds. R80633 has a MIC
of 511 nM against P1/Mahoney [17]. After an overnight
incubation of virus and compounds at 4‡C, the com-
pounds were put through our assay, and the resulting
matrix-assisted laser desorption ionization time-of-£ight
mass spectroscopy (MALDI-TOF) mass spectrum con-
tained only three peaks corresponding to the three com-
pounds. The control experiment (Fig. 4C) without virus in
the incubation gave no indication of R77975, R78206 or
R80633. An additional control in which only virus and no
compounds were present in the incubation was also
screened, giving no signal (Fig. 4D).
2.3. Mass spectrometry screenings of R78206, R80633 and
¢ve other compounds incubated with virus
To verify that the binding of drug to virus was speci¢c,
we constructed a test library containing two compounds
with proven antiviral activity, R78206 and R80633, along-
side a cocktail of ¢ve structurally related compounds (Fig.
2B) with di¡erent molecular weights and with no expected
ability to bind virus (unpublished crystallographic data).
In this incubation, each compound was present in an equi-
molar amount (4U1039 mol at a concentration of 5 WM),
and there were exactly enough binding sites to bind all of
the compounds. The MALDI-TOF spectrum from this
experiment indicated the expected peaks for R78206 and
R80633 (Fig. 4B). Of the other ¢ve compounds, a peak
was detected for IQ, indicating that it may be a weak
binder. All other molecular mass ion peaks for the other
compounds were absent.
2.4. Mass spectrometry screening of library A incubated
with virus
A library of 75 potential compounds was synthesized
using combinatorial chemistry (Fig. 3A). The design of
this library is a modi¢cation of a previously published
design based on computer modeling studies on the VP1
pocket of poliovirus and rhinovirus [22]. A 500 Wl incuba-
tion was set up such that the moles of the library com-
pounds were 15-fold greater than the moles of virus bind-
ing sites. Speci¢cally, the concentration of library was
3.24U1034 M in the incubation for a total of
1.62U1037 mol of compounds, while the concentration
of virus sites was 2.16U1035 M. Given these amounts,
there are enough sites to bind up to approximately ¢ve
compounds, assuming an equal yield of each library com-
pound. This incubation was run through the mass spec-
troscopic assay (Fig. 1) yielding the spectrum in Fig. 5A.
A second screening of library A was done under di¡er-
ent conditions to examine the ability of the assay to select
the same candidates. This incubation used a 10:1 ratio of
compound to binding sites and the concentration of li-
brary in the incubation was 1.2U1034 M. After the sam-
ple was dried to completion, it was re-suspended in 50 Wl
of methanol. Upon addition of methanol, a white precip-
itate formed. This material was precipitated by centrifuga-
tion at room temperature for 10 min at 17 000Ug. The
supernatant was separated, while the pellet easily re-sus-
pended in 50 Wl of ethanol. Both samples were analyzed by
electrospray mass spectrometry.
The results from both screens are shown in Fig. 5B,C.
The masses range of compounds in library A range from
Fig. 5. Mass spectrometry screen of library A. (A) MALDI-TOF spec-
trum of library A screened with P1/M. An K-cyano-4-hydrocinnamic
acid matrix peak is denoted M. When library A was re-screened using
electrospray mass analysis, the extracted material was ¢rst re-suspended
in methanol, which generated a precipitate. A spectrum of the superna-
tant was taken and shown in (B). The precipitate was re-suspended in
ethanol and its mass spectrum is shown in (C). Mass peaks correspond-
ing to compounds in the library are marked with asterisks.
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274 to 506 Da, but the spectra have been truncated for the
sake of clarity. All of the mass peaks which correspond to
compounds in library A are marked with an asterisk. In all
cases, there are a large number of peaks that cannot be
assigned to any compound in our libraries. These extra-
neous peaks may represent either impurities in the re-
agents used or small molecules (e.g. polyamines) that are
normally associated with the virus. The peaks may also
simply represent noise in the spectra, which is being pro-
duced near the sensitivity threshold of the available instru-
ment due to limitations in the amount of virus that it is
practical to use in a given experiment. Fortunately, the
identity of the extraneous peaks varies from assay to assay
and, in some cases, from shot to shot with a given sample,
whereas the peaks we have interpreted as true signal are
reproducible. Despite the great deal of noise, the MALDI-
TOF spectrum (Fig. 5A) consistently shows two peaks
corresponding to molecular masses of compounds in our
library. These are 289 and 414. The mass spectrum of the
precipitate (Fig. 5C) used in electrospray analysis yielded
four relatively strong peaks, corresponding to molecular
masses 304, 327, 343 and 367. The mass spectrum of the
supernatant (Fig. 5B) used in the electrospray analysis
con¢rmed 304 and 367, and added two other candidate
ligands, 383 and 397. In total, eight unique peaks were
identi¢ed from all spectra that could correspond to library
compounds. We attribute the di¡erences between the three
assays shown in Fig. 5 to di¡erences in sample handling
(e.g. di¡erential solubility in the solvents used to prepare
the extracted ligand for mass spectrometry) and to di¡er-
ences in the mechanisms for volatilizing samples in the two
mass spectrometry technologies. These di¡erences are ex-
acerbated by the fact that the assays are being run near the
sensitivity threshold of the available instruments and could
probably be overcome by using much larger amounts of
the virus in the samples.
2.5. Mass spectrometry screening of sub-library 6.1
incubated with virus
In order to improve the signal and to verify our results
from the library A screen, we synthesized a small combi-
natorial library (containing six compounds) that included
two of the compounds (304 and 367) that were identi¢ed
in the electrospray spectra (Fig. 2B). As shown in Fig. 6A,
screening of this library with the assay only re-produced
peak 367 from the library A screen. The absence of the
304 peak may indicate that its presence in the library A
screen was a false positive. Individual synthesis and
screening of 304 did not give a signal in our assay (data
not shown). Individual synthesis of 367 and a subsequent
re-analysis of 367 with P1/Mahoney returned the signal
(data not shown).
2.6. Mass spectrometry screening of sub-library 6.2
incubated with virus
Since the initial modeling work [22] suggested that the
central region of the pocket was capable of accepting larg-
er aromatic groups, another six compound library was
synthesized with the same terminal groups as in sub-li-
brary 6.1, but with the aliphatic linker being replaced
with a linker containing an aromatic ring (Fig. 2C). This
library includes two additional compounds (383 and 396)
that were identi¢ed in the original electrospray screen of
library A. As indicated only the larger compounds in sub-
library 6.2 bound to the virus (Fig. 6B). As with the sub-
library 6.1 screen, one of the candidates, 343, appeared to
be a false positive.
2.7. Rate constants of 160S to 135S conversion
We have previously shown that known capsid-binding
Fig. 6. MALDI-TOF mass spectrometry screen of sub-libraries. Sub-li-
brary 6.1 (A) and sub-library 6.2 (B) screened with P1/Mahoney. Mass
peaks in the spectra corresponding to compounds in the sub-libraries
are marked with asterisks. The matrix compound used in this experi-
ment was DHB, which does not produce characteristic peaks in the
mass range displayed.
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agents slow the rate of thermally induced 160s to 135S
conversion, and that there is a rough correlation between
the rate of conversion at a given temperature and the MIC
for the compound [18]. Determination of the rate constant
for this process can be calculated by immunoprecipitating
radiolabeled 135S particle as it is formed in vitro as a
function of time. Where possible the compound concen-
tration was arbitrarily set at 40 WM in conversion bu¡er
containing 0.1% dimethyl sulfoxide (DMSO). However,
some of the compounds or libraries, were not soluble to
that degree, so the concentrations listed in Fig. 7B repre-
sent nearly saturated solutions. Note also that the concen-
trations used are based on the mass of the dried oil and
are therefore very approximate and represent an upper
limit to the true concentration.
Fig. 7 shows the rate constants for the 160S to 135S
transition at 43‡C for 3H-P1/Mahoney which had been
pre-incubated with sub-library 6.1, sub-library 6.2, 280,
292, 304, 367, or 379, 383 and 396. Rates for virus alone
in 0.1% DMSO and for virus pre-incubated with R78206
and R77975 are shown as controls. We previously have
shown that 0.1% DMSO has no e¡ect on the rate constant
for the process, whereas higher concentrations can inhibit
the transition (data not shown). Library 6.1 and com-
pound 304 showed a marginally signi¢cant reduction in
the rate of conversion. The low level of protection af-
forded by library 6.1 may re£ect the low total drug con-
centration used in the assay due to solubility limitations.
Library 6.2 and three of the pure individually synthesized
compounds (367, 383 and 396) showed a signi¢cant reduc-
tion in the rate of conversion. The rate reduction observed
for 367 was comparable to that observed for R77975, even
though a much lower level of 367 was used due to solu-
bility limitations. The rate reduction observed for 383 and
396 were intermediate between those observed for R77975
(whose MIC for P1/Mahoney is 3 WM) and R78206
(whose MIC for P1/Mahoney is 0.008 WM).
2.8. Cell-based assays
To verify that the candidates from our screens might
protect cells from invasion by picornaviruses, we at-
tempted to determine the minimum inhibitory concentra-
tions of the compounds. When tested against P1/Mahoney
in a HeLa cell-based cytopathic e¡ect assay, the potency
of the three candidates, 367, 383 and 396, appeared to
correlate well to their rate constants (Table 2). None of
the other compounds tested exhibit any activity against
poliovirus at concentrations up to 25 WM. Six of the in-
dividually synthesized compounds (304, 355, 367, 379, 383
and 396) were tested in Viropharma’s automated infectiv-
ity assay against a variety of rhino- and enteroviruses
Table 2
Minimum inhibitory concentrations of candidates
(A) MIC versus poliovirus 1/Mahoney
Compound MIC (WM)
R78206 0.008a
R80366 0.511a
R77975 3.061a
396 11
383 0.26
367 3.2
(B) Human rhinoviruses
Compound HRV type IC50 (WM)
396 14 no activity
383 14 0.8
383 3 0.55
379 14 3.2
367 14 no activity
(A) MICs against poliovirus type 1. (B) IC50 against rhinovirus.
aThese values were previously presented in [17].
Fig. 7. Rate constants for the 160S to 135S transition in the presence of
various compounds at 43‡C. (A) Summary of rate constant plots. The
data for R77975 extends to 7 min, but the plot has been truncated for
the sake of clarity. (B) Table of rate constants for the compounds tested
at 43‡C.
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(HRV1A, 3, 14, 16, polio 1, 2 and 3 (Sabin strains), cox-
sackievirus B3 (Gauntt strain) and echovirus 30 (Bastianni
strain)). Compounds 304 and 355 had been submitted as
negative controls. Two of the compounds (379 and 383)
tested positive for HRV3 and 14. Curiously, the three
compounds that reproducibly showed activity against the
Mahoney strain of type 1 poliovirus in our thermal con-
version and infectivity assays failed to show activity
against the Sabin strain of any of the three serotypes of
poliovirus in the Viropharma assay. This may be due to
di¡erences between the closely related Sabin and Mahoney
strains of type 1 poliovirus. Compound 383 was found to
be slightly toxic at 25 WM, but this concentration is s 10U
the IC50 for P1/Mahoney, HRV3 and HRV14.
3. Discussion
Despite advances in structure-based design methods and
the vast ligand diversity provided by combinatorial chem-
istry, rational drug development remains an immature and
imprecise art. Indeed, the successful applications of struc-
ture-based design approaches to date generally have been
restricted to developing existing leads identi¢ed by conven-
tional methods and have largely focused on enzyme tar-
gets. The arguably more di⁄cult goal of utilizing structure
to discover new lead compounds or to develop drugs
against targets that are not enzymes is far less well devel-
oped. Given the large (and increasing) number of high
resolution structures of appropriate targets, we believe
the limited success of the structure-based methods is at-
tributable to several factors, including inherent limitations
in the accuracy of even the best structures, the lack of
general computational approaches to predict the free en-
ergy of binding, and the paucity of tools to facilitate the
translation of structure into synthesizable ligands. In con-
trast, combinatorial chemistry has been typically used to
identify leads that are developed by conventional SAR
methods. However, the synthesis of highly diverse combi-
natorial libraries, has proven more challenging than many
had predicted. Moreover, the vast majority of diversity of
libraries is wasteful for any given target, especially when
other information is available, e.g. a structure of the tar-
get, a lead or a known enzyme mechanism. Wasted diver-
sity places unnecessary demands on synthetic methods and
particularly on the screening assays, because noise contrib-
uted by the plethora of weak binders in a library can mask
the signal of strong binders. The complementarity between
the strengths and weaknesses of structure-based and com-
binatorial approaches immediately suggests the utility of a
hybrid approach, in which the structure of a target is used
to develop structurally biased combinatorial libraries
whose focused diversity in ‘regions of chemical space’
are likely to be productive.
We have used such a hybrid approach to design new
leads in a family of antiviral drugs that inhibit replication
of enteroviruses and rhinoviruses by binding to the virions
and inhibiting conformational changes that are required
for receptor binding or cell entry. Although several mem-
bers of this family of antivirals have been described pre-
viously and structures of virus^drug complexes were
available prior to this work, the design did not make ex-
plicit use of the known drugs or virus^drug complexes,
with the exception of using the complexes to de¢ne the
binding site in the virus. Indeed, in retrospect, one could
argue that prior knowledge of the binding site was not
necessary based on three observations: (i) the binding
site is occupied by a natural ligand (or pocket factor) in
the structures of most rhino- and enteroviruses; (ii) genetic
studies in poliovirus have demonstrated that the ligand
binding site is important in regulating virus stability and
cell entry [25,26] and (iii) simple modeling demonstrates
that the natural ligand does not optimally ¢ll the binding
site, suggesting that larger ligands might bind more
strongly.
We have used fragment binding maps generated by the
program MCSS to develop a general template that has
served as a structural bias for limited combinatorial libra-
ries of compounds. A library containing 75 compounds
has been characterized using a high throughput mass spec-
trometric assay capable of identifying ligands from crude
libraries that bind virus. The screens identi¢ed three new
anti-picornaviral compounds. Two of these leads possess
large aromatic groups in the center of the molecule, mak-
ing them very di¡erent in structure from previously de-
scribed active antivirals at the time that these studies
were initiated (see below). The selection of three leads
from this library with micromolar and submicromolar ac-
tivity represents a highly respectable 10% success rate.
The activity of our leads was con¢rmed by a rapid ki-
netic assay and a traditional cytopathic inhibition assay.
While the ordering of MICs and degree of rate constant
inhibition does not directly correlate, the di¡erence in rate
constant inhibition between active compounds and poorly
or non-active compounds is readily apparent (Fig. 7). Our
data suggest that the IP assay provides good predictive
values in a shorter time scale than the common cell-based
assay. Moreover, because the virus is generally less sensi-
tive to solvent and impurities (including unreacted starting
materials) than cultured cells, the IP assay can be per-
formed with crude libraries, eliminating the need for rig-
orous puri¢cation at early steps in the process. The com-
bined screens identi¢ed three compounds (367, 383 and
396) that are active against the Mahoney strain of type
1 poliovirus. All of these compounds were micromolar
inhibitors, with MICs of 11, 3.2 and 0.26 WM for 396,
367 and 383, respectively. In an automated screen versus
a range of rhino- and enteroviruses, compound 383 also
was shown to be active versus rhinovirus 3 (IC50 = 0.55
WM) and rhinovirus 14 (IC50 = 0.8 WM), and another com-
pound (379) was shown to be active versus rhinovirus 14
(IC50 = 3.2 WM). We have solved the structures of com-
CHBIOL 50 7-2-01
Research Paper A high-throughput screen for anti-picornaviral compounds S.K. Tsang et al. 41
plexes of P1/Mahoney and two of our candidate drugs
(367 and 396) [27]. Interestingly, although both com-
pounds bound in the VP1 pocket, low contour maps of
the P1/M^367 complex revealed an alternate and signi¢-
cantly di¡erent binding mode from those previously re-
ported. We are presently attempting to use this informa-
tion in our design e¡orts.
The synthetic approach used in the generation of our
pilot libraries is quite robust and could easily be used to
create larger libraries of compounds from readily available
and inexpensive starting reagents. Such libraries could be
expected to generate additional ligands, some of which
may have signi¢cantly better MIC’s or a broader range
that any of those identi¢ed to date. Indeed, after our
work using this strategy began, Schering-Plough published
a compound that could be synthesized using our ap-
proach, having a V10 nM MIC against polio and micro-
molar or submicromolar activity against a broad range of
enterovirus [28^30].
One of the major problems limiting the size of libraries
that can be screened is the noise level of the mass spectro-
metric assay. Even with the present state-of-the-art mass
spectrometers, the noise level would preclude screening
libraries much larger than 100^200 compounds in the as-
say as presently formatted. Although this could be allevi-
ated by using larger amounts of virus in the assay, this
would ultimately become prohibitively expensive. An al-
ternative approach that is suggested by our subscreening
small 6^10 compound libraries would be to synthesize a
number of small libraries, each of which asked a ‘question’
about optimal components for the ‘head groups’ and ‘link-
ers’. Such libraries could be then screened in small groups
and the information gained from each group used in the
design of the next round of small libraries. These groups
of sub-libraries could be considered as components of a
sparse matrix or limited factorial screen that could be
analyzed by standard data mining approaches. This struc-
turally biased factorial approach could be used to e⁄-
ciently sample a large volume of the entire ‘chemical
space’ than would be feasible with the full combinatorial
approach.
4. Signi¢cance
We have developed and utilized a rapid, high-through-
put mass spectrometry assay for the identi¢cation of new
broad spectrum anti-picornaviral compounds from combi-
natorial libraries. The design of our test library was guided
by structure-based modeling into the VP1 pocket of both
P3/Sabin poliovirus and rhinovirus 14. Candidates identi-
¢ed in the mass spectrometry assay were veri¢ed by syn-
thesizing smaller sub-libraries containing the candidates
and re-screening with the assay. Veri¢ed candidates were
tested for inhibition of the rate constant for viral uncoat-
ing using an immunoprecipitation assay. These results
were compared against the MIC from traditional cell-
based assays. Using this procedure we isolated eight po-
tential candidates from a 75 compound library. Of these
eight, the ¢eld was narrowed to three, and the most prom-
ising lead appears to have a structure unlike previously
described inhibitors. These results demonstrate the utility
of structurally biased combinatorial approaches to ligand
design.
5. Materials and methods
5.1. Growth, propagation and puri¢cation of virus
P1/Mahoney was grown in HeLa cells grown in suspension and
puri¢ed by di¡erential centrifugation and CsCl density gradient
fractionation as described previously [31]. To label the virus with
3H-leucine, a protocol similar to that published earlier [32] was
used. Puri¢ed virus was dialyzed into phosphate-bu¡ered saline
(PBS) and concentrated to 5 mg/ml or greater by ultra¢ltration.
5.2. Synthesis of a large (bis)thioether library (library A)
One equivalent of equimolar amounts of the nucleophilic thi-
ophenols (Fig. 3) was dissolved in dimethylformamide (DMF)
under dry nitrogen. Ten equivalents of potassium carbonate
were added as a solid, and the solution was stirred at room
temperature for 5 min. To the resulting mixture was added half
an equivalent of an equimolar solution of the allyl- or aryl-di-
bromide building blocks in DMF. The reaction mixture was
stirred at room temperature for 24 h. Insoluble salts were re-
moved by ¢ltration, and the solution was concentrated to dryness
at reduced pressure. The residue was partitioned between ethyl
acetate and saturated aqueous sodium bicarbonate to remove
unreacted starting materials. The organic phase was further
washed with water and saturated aqueous sodium chloride, dried
over magnesium sulfate, and concentrated under vacuum. The
resulting brown oil was decolorized with Norit A as a solution
in 1:1 chloroform:methanol and redried.
5.3. Synthesis of sub-libraries 6.1 and 6.2
One equivalent of equimolar amounts of the nucleophilic thi-
ophenols was dissolved in DMF under dry nitrogen. Ten equiv-
alents of potassium carbonate was added as a solid, and the so-
lution was stirred at room temperature for 5 min. To the resulting
mixture was added half an equivalent of an equimolar solution of
the dibromide building blocks in DMF. The reaction mixture was
stirred at 60‡C for 24 h. The mixture was then diluted in water
and extracted three times with methylene chloride. The organic
layers were combined and washed three times with 0.1 N sodium
hydroxide, dried with potassium sulfate and concentrated under
vacuum. The resulting brown oil was decolorized with activated
charcoal as a solution in boiling ethanol and ¢ltered through a
bed of Celite. Concentration under vacuum gave a light brown
oil.
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5.4. Synthesis of single compounds
Reaction conditions were the same as for the large and small
bis-thioether libraries. After working up, washing, drying and
concentrating as described in Section 5.3, the desired compound
was isolated by silica gel chromatography. Compound identity
was con¢rmed by proton nuclear magnetic resonance and the
presence of molecular ion peak in fast atom bombardment
mass spectra.
5.5. Formation of virus^compound complexes for mass spectral
analysis
One hundred Wg of virus was incubated overnight at 4‡C with a
single compound or mixture of compounds in a 500 Wl low-bind-
ing microcentrifuge tube (Marsh Biomedical). Antiviral com-
pounds were supplied as powders or oils and concentrated stock
solutions were made in DMSO. Prior to incubation with virus,
aliquots of the libraries were assayed by mass spectrometry to
con¢rm their composition. With the exception of the parent 75
compound library, where only a subset (43%) of the possible
compounds were in the library at detectable levels, all of the
libraries were shown to be complete. The stocks were diluted
into conversion bu¡er (10 mM HEPES pH7.5, 2 mM CaCl2,
0.1% Triton X-100). The total incubation volume was 75 Wl
and the DMSO content in the incubations was always 5%. The
compound to pocket ratio in the incubations ranged from 1:1 to
333:1. The concentration of compounds in these incubations var-
ied from 1 WM to 2 mM.
5.6. Puri¢cation of compounds bound to virus (Fig. 1)
The virus^compound incubations were loaded onto Bio-Spin
columns (BioRad) with either a 6 or 30 kDa molecular mass cut-
o¡, which had been equilibrated in water to eliminate salts, which
can interfere with mass analysis. The columns were spun at
2000Ug in a Beckman J-6B centrifuge with a swinging bucket
rotor at room temperature. The ¢ltrate containing the virus was
transferred to a low-binding microcentrifuge tube. Subsequently,
200 Wl of ethyl acetate (Sigma) was added to the ¢ltrate. Each
sample was vortexed for 30 s, and the emulsi¢cation was removed
by spinning each sample at 16 000Ug for 5 min at room temper-
ature. The ethyl acetate organic solvent has a dual purpose: to
denature the virus, thereby liberating any virus-bound com-
pound, and to partition the hydrophobic compounds into the
organic phase. After spinning, the organic phase was transferred
to a new low-binding microcentrifuge tube. The compound-en-
riched ethyl acetate phase was dried down in a centrivap (Lab-
conco) with heat.
5.7. MALDI-TOF analysis of compounds
To each tube containing the dried compounds, 5 Wl of 70%
AcN 0.1% tri£uoroacetic acid (TFA) was added and vortexed
well to re-suspend the compounds. One Wl of this solution was
spotted onto a sample planchette with 1 Wl of matrix solution (see
below). The remainder of the sample was re-dried and re-sus-
pended in 1 Wl of 70% AcN 0.1% TFA and spotted with 1 Wl
of matrix solution. Samples were allowed to crystallize at room
temperature. The crystalline samples were redissolved on the sam-
ple planchette with the addition of 0.5 Wl of 70% AcN 0.1% TFA
to create a more homogeneous sample spot.
Our initial experiments involved using a matrix of saturated
sinapinic or K-cyano-4-hydrocinnamic acid (Sigma) in 70% AcN
0.1% TFA. However, since the matrix peaks for sinapinic acid
tended to interfere with those of our compounds, we switched to
30 mg/ml 2,5-dihydroxybenzoic acid (DHB) (Sigma) also dis-
solved in 70% AcN 0.1% TFA.
Samples were analyzed on a Voyager-DE STR MALDI-TOF
mass spectrometer from Perceptive Biosystems (Framingham,
MA, USA) in re£ectron mode. For every session prior to analy-
sis, the mass spectrometer was calibrated to a bradykinin mass
standard (904.4) and one of the matrix peaks, either 225.1 for
sinapinic acid or 154.0 for DHB. In MALDI-TOF spectra, the
value of each peak is one greater than the molecular mass of the
corresponding analyte, because each molecule is ionized in the
process.
5.8. Electrospray mass analysis of compounds
After the material was screened and dried down, the residue
was re-suspended in either methanol or ethanol, two solvents
used commonly in electrospray mass spectrometry. Samples
were analyzed on a Micromass spectrometer (UK). Unlike MAL-
DI-TOF, peaks in electrospray mass spectra correspond directly
to the analyte’s true mass.
5.9. Formation of virus^compound complexes for kinetic
experiments
In a 22.5 Wl volume, 11 Wg of 3H-P1/Mahoney was incubated in
a 10^40 WM solution of a single compound or small library. The
DMSO concentration in these incubations did not exceed 0.1%,
which is known to have no a¡ect on the rate of uncoating (un-
published results). The incubations were brought up to volume
using conversion bu¡er. These incubations were performed over-
night at 4‡C in low-binding microcentrifuge tubes.
5.10. Immunoprecipitation of 135S
The rate of thermal induced 160S to 135S conversion of virus
drug complexes was determined as described elsewhere [18].
Brie£y 980 Wl of conversion bu¡er in a 1.5 ml Eppendorf tube
was pre-warmed to the speci¢ed temperature in a water bath
(Isotemp Refrigerated Circulator Model 9100, Fisher Scienti¢c).
The 980 Wl of bu¡er contained the compound or library of inter-
est at the same concentration as in the overnight incubation. The
temperature was monitored by inserting a thermocoupler probe
(Omega) into a 1.5 ml Eppendorf tube which had 1 ml of con-
version bu¡er. When the temperature had stabilized for at least
5 min the experiment was allowed to proceed.
Prior to use, the virus^compound incubation was equilibrated
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at room temperature by letting it sit on the bench top for at least
10 min. Since the 135S particle is very hydrophobic, minimizing
the degree of loss of 135S to non-speci¢c binding required using
siliconized tips (VWR) on all solutions potentially containing the
135S particle. Twenty Wl of the virus^compound incubation was
added to the pre-warmed bu¡er and the entire reaction tube was
removed from the water bath and vortexed vigorously and re-
turned to the water bath within 3 s. At the appropriate time
interval, an 80 Wl aliquot was removed and transferred to a
low-binding microcentrifuge tube containing 50 Wl of ice-cold
PBS+bu¡er (PBS, 1% Triton X-100, 0.1% SDS, 0.5 mg/ml bovine
serum albumin, 0.01% NaN3). The purpose of the chilled bu¡er is
to rapidly bring down the temperature of the aliquot to stop the
conversion of native virus into the 135S form.
Thirty-¢ve Wl of P1 monoclonal antibody was added to each
aliquot. This antibody binds residues 24^40 of the N-terminal end
of VP1 which is internal in the native virus but has been shown to
be exposed upon the 160S to 135S transition [33]. The amount of
antibody required to pull down all of the A particle in an aliquot
assuming complete conversion had been pre-determined by stan-
dard curve. The incubation was carried out at room temperature
for 1 h to allow immune complexes to form. Subsequently, 40 Wl
of protein A Sepharose CL-4B (Pharmacia) was added to each
tube. The tubes were shaken to keep the protein A beads in
suspension for 2 h at 4‡C. The beads were washed 3^4 times
with 300 Wl PBS+bu¡er. After each wash, the beads were pelleted
by centifugation at 16 000Ug for 5 min at room temperature. The
washes were combined and the pooled wash and the beads were
transferred to separate vials containing 7 ml of scintillation £uid
(EcoScintA, national diagnostics). The counts in the pellet and
supernatant fractions were determined by scintillation counting
(LS500TD, Beckman).
5.11. Determination of rate constants
The percentage of 160S at each time point was calculated by
using:
total cpm3bead cpm=total cpm
where the total cpm is the sum of the counts per minute (cpm) of
the washes and bead cpm is the cpm of the beads. The ¢rst order
rate constants for the conversion were determined by determining
the slope of the plot of the log of the percent remaining 160S at
each time point versus time using Kaleidagraph 3.0 (Abelbeck
Software).
5.12. Cytopathic e¡ect assays
In a 96-well plate, 1000 pfu of virus was incubated with a drug
dilution at a ¢nal DMSO concentration of 1.5% for 1 h at 37‡C.
The volume of this incubation was brought up to 100 Wl with
Dulbecco’s modi¢ed Eagle’s medium (DMEM; Gibco), 10% fetal
bovine serum, 40 mM MgCl2, 3.7% Na2HCO3, 1U non-essential
amino acids (Gibco), 1U Pen/Strep (Gibco). All drug stocks were
made in 100% DMSO. The virus stock was in PBS. After pre-
incubating the virus with the compounds, 1U104 HeLa cells in a
50 Wl volume of the DMEM solution above was added to each
well. After 2 days at 37‡C in a humidi¢ed 5% CO2 incubator, the
plates were ¢xed with 7% formaldehyde, then stained with 0.1%
crystal violet. The MIC was the minimum concentration of com-
pound required to prevent complete lysis of all cells. Six of the
most promising candidates were screened by Viropharma for
their ability to inhibit a panel of enteroviruses and rhinoviruses
using their standard high-throughput screen. Results of these as-
says were reported as IC50 values, which corresponds to the con-
centration of compound required to protect 50% of the cells in
the well plate.
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